questionsmedicales.fr
Composés hétérocycliques
Composés hétéromonocycliques
Pyridines
Composés de pyridinium
1-Méthyl-4-phényl-pyridinium
1-Méthyl-4-phényl-pyridinium : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Maladie de Parkinson
Neurotoxicité
Imagerie par résonance magnétique
Électromyographie
Analyse sanguine
Toxicologie
Évaluation neurologique
Réflexes
Symptômes
5
Tremblements
Troubles de la marche
Troubles cognitifs
Démence
Système nerveux
Neurones dopaminergiques
Douleurs musculaires
Douleurs articulaires
Prévention
5
Prévention
Équipements de protection
Vaccins
Prévention des maladies
Mode de vie sain
Maladies neurodégénératives
Éducation à la santé
Sensibilisation
Contrôles médicaux
Détection précoce
Traitements
5
Médicaments dopaminergiques
Thérapie physique
Réhabilitation
Qualité de vie
Antioxydants
Stress oxydatif
Acupuncture
Thérapies complémentaires
Traitement précoce
Progression des symptômes
Complications
5
Complications
Troubles moteurs
Chutes
Troubles de la marche
Qualité de vie
Symptômes parkinsoniens
Complications cardiovasculaires
Santé cardiovasculaire
Facteurs de risque
5
Facteurs de risque
Pesticides
Antécédents familiaux
Maladies neurodégénératives
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1-Méthyl-4-phényl-pyridinium : Questions médicales les plus fréquentes",
"headline": "1-Méthyl-4-phényl-pyridinium : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1-Méthyl-4-phényl-pyridinium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-14",
"dateModified": "2025-03-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1-Méthyl-4-phényl-pyridinium"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composés de pyridinium",
"url": "https://questionsmedicales.fr/mesh/D011726",
"about": {
"@type": "MedicalCondition",
"name": "Composés de pyridinium",
"code": {
"@type": "MedicalCode",
"code": "D011726",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "1-Méthyl-4-phényl-pyridinium",
"alternateName": "1-Methyl-4-phenylpyridinium",
"code": {
"@type": "MedicalCode",
"code": "D015655",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hemmige S Yathirajan",
"url": "https://questionsmedicales.fr/author/Hemmige%20S%20Yathirajan",
"affiliation": {
"@type": "Organization",
"name": "Department of Studies in Chemistry University of Mysore, Manasagangotri, Mysore-570 006, India."
}
},
{
"@type": "Person",
"name": "Yuka Yamamoto",
"url": "https://questionsmedicales.fr/author/Yuka%20Yamamoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. yuka@kms.ac.jp."
}
},
{
"@type": "Person",
"name": "Katsuya Mitamura",
"url": "https://questionsmedicales.fr/author/Katsuya%20Mitamura",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan."
}
},
{
"@type": "Person",
"name": "Jun Toyohara",
"url": "https://questionsmedicales.fr/author/Jun%20Toyohara",
"affiliation": {
"@type": "Organization",
"name": "Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Takashi Norikane",
"url": "https://questionsmedicales.fr/author/Takashi%20Norikane",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Temporal lobe epilepsy.",
"datePublished": "2023-01-30",
"url": "https://questionsmedicales.fr/article/36718887",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4045/tidsskr.22.0369"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anterior nucleus of the thalamus deep brain stimulation vs temporal lobe responsive neurostimulation for temporal lobe epilepsy.",
"datePublished": "2022-07-05",
"url": "https://questionsmedicales.fr/article/35704344",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/epi.17331"
}
},
{
"@type": "ScholarlyArticle",
"name": "Model Sharing in the Human Medial Temporal Lobe.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35606146",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1523/JNEUROSCI.1978-21.2022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Involuntary memory signals in the medial temporal lobe.",
"datePublished": "2023-11-14",
"url": "https://questionsmedicales.fr/article/37961773",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/S0140525X23000067"
}
},
{
"@type": "ScholarlyArticle",
"name": "Critical role of the ventral temporal lobe in naming.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36806185",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/epi.17555"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pyridines",
"item": "https://questionsmedicales.fr/mesh/D011725"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composés de pyridinium",
"item": "https://questionsmedicales.fr/mesh/D011726"
},
{
"@type": "ListItem",
"position": 6,
"name": "1-Méthyl-4-phényl-pyridinium",
"item": "https://questionsmedicales.fr/mesh/D015655"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1-Méthyl-4-phényl-pyridinium - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1-Méthyl-4-phényl-pyridinium",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1-Méthyl-4-phényl-pyridinium",
"description": "Comment diagnostiquer l'exposition au MPP+ ?\nQuels examens sont recommandés pour le MPP+ ?\nQuels symptômes indiquent une intoxication au MPP+ ?\nLe MPP+ peut-il être détecté dans le sang ?\nQuels tests neurologiques sont utiles pour le MPP+ ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Temporal+Lobe#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quels sont les symptômes principaux du MPP+ ?\nLe MPP+ cause-t-il des troubles cognitifs ?\nY a-t-il des symptômes non moteurs liés au MPP+ ?\nComment le MPP+ affecte-t-il le système nerveux ?\nLe MPP+ provoque-t-il des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Temporal+Lobe#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1-Méthyl-4-phényl-pyridinium",
"description": "Comment prévenir l'exposition au MPP+ ?\nY a-t-il des vaccins contre le MPP+ ?\nLes changements de mode de vie aident-ils à prévenir le MPP+ ?\nL'éducation sur le MPP+ est-elle importante ?\nLes contrôles réguliers sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Temporal+Lobe#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quels traitements sont efficaces contre le MPP+ ?\nLa réhabilitation est-elle utile pour les patients exposés au MPP+ ?\nPeut-on utiliser des antioxydants pour traiter le MPP+ ?\nLes thérapies complémentaires sont-elles bénéfiques ?\nLe traitement précoce du MPP+ est-il crucial ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Temporal+Lobe#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quelles complications peuvent survenir avec le MPP+ ?\nLe MPP+ peut-il entraîner des chutes ?\nY a-t-il un risque accru de dépression avec le MPP+ ?\nLe MPP+ peut-il affecter la qualité de vie ?\nDes complications cardiovasculaires sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Temporal+Lobe#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quels sont les principaux facteurs de risque du MPP+ ?\nL'âge est-il un facteur de risque pour le MPP+ ?\nLes antécédents familiaux influencent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de MPP+ ?\nLe mode de vie influence-t-il le risque de MPP+ ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Temporal+Lobe#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'exposition au MPP+ ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biologiques et des évaluations neurologiques sont utilisés pour diagnostiquer l'exposition."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour le MPP+ ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et l'électromyographie peuvent aider à évaluer les dommages neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication au MPP+ ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tremblements, rigidité et bradykinésie peuvent indiquer une intoxication au MPP+."
}
},
{
"@type": "Question",
"name": "Le MPP+ peut-il être détecté dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des analyses sanguines peuvent détecter la présence de MPP+."
}
},
{
"@type": "Question",
"name": "Quels tests neurologiques sont utiles pour le MPP+ ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de coordination et de réflexes peuvent évaluer l'impact neurologique du MPP+."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux du MPP+ ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent tremblements, rigidité musculaire et troubles de la marche."
}
},
{
"@type": "Question",
"name": "Le MPP+ cause-t-il des troubles cognitifs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au MPP+ peut entraîner des troubles cognitifs et de la mémoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes non moteurs liés au MPP+ ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la dépression et l'anxiété peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment le MPP+ affecte-t-il le système nerveux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le MPP+ endommage les neurones dopaminergiques, entraînant des symptômes parkinsoniens."
}
},
{
"@type": "Question",
"name": "Le MPP+ provoque-t-il des douleurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires et articulaires peuvent être présentes chez les patients."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au MPP+ ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les environnements contaminés et utiliser des équipements de protection."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins contre le MPP+ ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin spécifique contre le MPP+."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils à prévenir le MPP+ ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "L'éducation sur le MPP+ est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques et les symptômes est essentielle pour la prévention."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers sont-ils recommandés ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers peuvent aider à détecter précocement les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre le MPP+ ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments dopaminergiques et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "La réhabilitation est-elle utile pour les patients exposés au MPP+ ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhabilitation aide à améliorer la mobilité et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des antioxydants pour traiter le MPP+ ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antioxydants peuvent être envisagés pour réduire le stress oxydatif lié au MPP+."
}
},
{
"@type": "Question",
"name": "Les thérapies complémentaires sont-elles bénéfiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies complémentaires, comme l'acupuncture, peuvent soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Le traitement précoce du MPP+ est-il crucial ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement précoce peut ralentir la progression des symptômes parkinsoniens."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le MPP+ ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles moteurs sévères et des problèmes cognitifs."
}
},
{
"@type": "Question",
"name": "Le MPP+ peut-il entraîner des chutes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles de la marche augmentent le risque de chutes chez les patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de dépression avec le MPP+ ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients exposés au MPP+ présentent un risque accru de dépression."
}
},
{
"@type": "Question",
"name": "Le MPP+ peut-il affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes parkinsoniens peuvent significativement réduire la qualité de vie."
}
},
{
"@type": "Question",
"name": "Des complications cardiovasculaires sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre MPP+ et complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du MPP+ ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition à des pesticides et à des produits chimiques industriels augmente le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour le MPP+ ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'effets néfastes du MPP+ augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies neurodégénératives augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de MPP+ ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que les hommes sont plus à risque que les femmes."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de MPP+ ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/03/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Department of Studies in Chemistry University of Mysore, Manasagangotri, Mysore-570 006, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
3-Methyl-5-(4-methyl-phen-oxy)-1-phenyl-1
IUCrData
2022-09-27
Crystal structure studies of 4-ethyl-piperazin-1-ium 3,5-di-nitro-benzoate, 4-methyl-piperazin-1-ium 3,5-di-nitro-benzoate and 4-methyl-piperazin-1-ium 4-iodo-benzoate.
Acta crystallographica. Section E, Crystallographic communications
2021-10-21
Crystal-structure studies of 4-phenyl-piperazin-1-ium 4-eth-oxy-benzoate monohydrate, 4-phenyl-piperazin-1-ium 4-meth-oxy-benzoate monohydrate, 4-phenyl-piperazin-1-ium 4-methyl-benzoate monohydrate and 4-phenyl-piperazin-1-ium tri-fluoro-acetate 0.12-hydrate.
Acta crystallographica. Section E, Crystallographic communications
2022-06-10
5-(4-Fluoro-phen-yl)-1-[4-(4-methyl-phen-yl)thia-zol-2-yl]-3-[4-(prop-2-yn-yloxy)phen-yl]-4,5-di-hydro-1
IUCrData
2022-10-25
Syntheses and crystal structures of 4-(4-meth-oxy-phen-yl)piperazin-1-ium 4-methyl-benzoate monohydrate and bis-[4-(4-meth-oxy-phen-yl)piperazin-1-ium] benzene-1,2-di-carboxyl-ate.
Acta crystallographica. Section E, Crystallographic communications
2022-08-26
4 publications dans cette catégorie
Affiliations :
Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. yuka@kms.ac.jp.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
4 publications dans cette catégorie
Affiliations :
Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
4 publications dans cette catégorie
Affiliations :
Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
4 publications dans cette catégorie
Affiliations :
Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
4 publications dans cette catégorie
Affiliations :
Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
3 publications dans cette catégorie
Affiliations :
Department of Chemistry, Howard University, 525 College Street NW, Washington DC 20059, USA.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
3 publications dans cette catégorie
Affiliations :
Department of Physics, Faculty of Sciences, Erciyes University, 38039 Kayseri, Türkiye.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
Crystal structures and Hirshfeld surface analyses of methyl 4-{2,2-di-chloro-1-[(
Acta crystallographica. Section E, Crystallographic communications
2024-01-26
Crystal-structure studies of 4-phenyl-piperazin-1-ium 4-eth-oxy-benzoate monohydrate, 4-phenyl-piperazin-1-ium 4-meth-oxy-benzoate monohydrate, 4-phenyl-piperazin-1-ium 4-methyl-benzoate monohydrate and 4-phenyl-piperazin-1-ium tri-fluoro-acetate 0.12-hydrate.
Acta crystallographica. Section E, Crystallographic communications
2022-06-10
Crystal structures of 1-(4-chloro-phen-yl)-4-(4-methyl-phen-yl)-2,5-dioxo-1,2,5,6,7,8-hexa-hydro-quinoline-3-carb-oxy-lic acid and 4-(4-meth-oxy-phen-yl)-1-(4-methyl-phen-yl)-2,5-dioxo-1,2,5,6,7,8-hexa-hydro-quinoline-3-carbo-nitrile.
Acta crystallographica. Section E, Crystallographic communications
2021-03-05
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Neuroprotective Drug Discovery Center, Nanjing Medical University, Nanjing, China.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Pharmacy, Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Neuroprotective Drug Discovery Center, Nanjing Medical University, Nanjing, China.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Studies in Chemistry University of Mysore, Manasagangotri, Mysore-570 006, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Studies in Chemistry Mangalore University Mangalagangotri, Mangalore-574 199, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Studies in Chemistry Mangalore University Mangalagangotri, Mangalore-574 199, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Thomas Jefferson High School for Science and Technology, 6560 Braddock Rd Alexandria VA 22312, USA.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, School of Basic Sciences and Research, Sharda University, Greater Noida 201306, India.
Department of Chemistry, Pondicherry University, Puducherry 605 014, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Pondicherry University, Puducherry 605 014, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida 201306, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore-570 006, India.
Publications dans "1-Méthyl-4-phényl-pyridinium" :
The temporal lobes are the part of the brain most likely to give rise to epileptic seizures. Seizures originating in the temporal lobes vary greatly in character; some may be so unusual that they are ...
Based on the promising results of randomized controlled trials, deep brain stimulation (DBS) and responsive neurostimulation (RNS) are used increasingly in the treatment of patients with drug-resistan...
We performed a retrospective review of patients who were treated with either ANT-DBS or TL-RNS for drug-resistant TLE with at least 12 months of follow-up. Along with the clinical characteristics of e...
Twenty-six patients underwent ANT-DBS implantation and 32 patients underwent TL-RNS for drug-resistant TLE. The epilepsy characteristics of both groups were similar. Patients who underwent ANT-DBS dem...
We demonstrate in our single-center experience that patients with drug-resistant TLE benefit similarly from either ANT-DBS or TL-RNS. Selection of either ANT-DBS or TL-RNS may, therefore, depend more ...
Effective planning involves knowing where different actions take us. However, natural environments are rich and complex, leading to an exponential increase in memory demand as a plan grows in depth. O...
We highlight recent progress in neuroimaging and neuropsychological research on memory mechanisms in the medial temporal lobe that speaks to the involuntary nature of memory retrieval processes. We su...
Lexical retrieval deficits are characteristic of a variety of different neurological disorders. However, the exact substrates responsible for this are not known. We studied a large cohort of patients ...
We performed a multivariate voxel-based lesion-symptom mapping analysis to correlate surgical lesions within the temporal lobe with changes in naming ability. Additionally, we used a surface-based mix...
We observed that ventral temporal regions, centered around the middle fusiform gyrus, were significantly associated with a decline in naming. Furthermore, we found that the ventral aspect of temporal ...
Taken together, these data highlight the crucial contribution of the ventral temporal cortex in naming and its important role in the pathophysiology of anomia following temporal lobe resections. As su...
Non-invasive imaging studies play a critical role in the presurgical evaluation of patients with drug-resistant temporal lobe epilepsy (TLE), particularly in helping to lateralize the seizure focus. A...
Twenty TLE patients (9 MRI+, 11 MRI-) and 14 HVs under went 3 T Pseudo-Continuous ASL MRI through an epilepsy imaging research protocol at the NIH Clinical Center. We compared normalized CBF and absol...
Compared to HVs, both MRI+ and MRI- TLE groups demonstrated significant ipsilateral mesial and lateral temporal hypoperfusion, specifically in the hippocampal and anterior temporal neocortical subregi...
We found a similar extent of interictal ipsilateral temporal hypoperfusion in MRI+ and MRI- TLE. However, significantly increased asymmetries were found only in the MRI+ group due to differences in pe...
Temporal lobe encephaloceles (TEs) are a rare cause of drug-resistant temporal lobe epilepsy (DR-TLE), with head trauma and obesity identified as risk factors in adults. This study evaluated the clini...
This is a single-institution retrospective review of childhood-onset DR-TLE with radiographic TE identified between 2008 and 2020. The epilepsy history, brain imaging features, and surgical outcomes w...
Eleven children with DR-TLE due to TE were included (median age at epilepsy onset was 11 years, interquartile range 8.5 to 13.5 years). Median latency between epilepsy diagnosis and TE detection was 3...
TE is a surgically remediable etiology of DR-TLE in childhood. TEs are often overlooked at pediatric epilepsy diagnosis, calling for the need to increase awareness of this entity. FDG-PET temporal hyp...
This study aimed to evaluate the use of diffusion kurtosis imaging (DKI) to detect microstructural abnormalities within the temporal pole (TP) and its temporopolar cortex in temporal lobe epilepsy (TL...
The currently available evidence is unclear in regard to psychiatric outcomes of temporal lobe epilepsy (TLE) in patients with comorbid psychiatric disorders (PD)....
To identify and synthesize psychiatric outcomes in patients with TLE and comorbid psychiatric illnesses before and after TLE surgery....
Studies were included if participants were adults and/or children with temporal epilepsy and comorbid psychiatric illness. Surgical interventions included focal resection (e.g., lobectomy, selective a...
Ten studies were included in the review. The proportion of patients achieving PD resolution or improvements after surgery varied widely between studies, ranging from 15 % to 57 % at the reported follo...
A considerable proportion of reported TLE patients with comorbid psychiatric illnesses have improvement in their psychiatric symptoms after temporal lobe epilepsy surgery. There is scarcity of detaile...
Impaired processing speed (PS) can affect patients with temporal lobe epilepsy (TLE). However, it is usually considered a nonspecific clinical feature and is not measured, but this raises lexical and ...
A scoping review was conducted based on the extended guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The electronic literature search was conducted on Medline-Pub...
Seven articles published between December 2004 and September 2021 were selected. The terms "processing speed," "psychomotor speed," and "information processing speed," based on similar theoretical con...
Clinical research on TLE has focused inconsistently on PS. Different evaluation terms and methods have been used while referring to similar theoretical constructs. These findings highlight a gap betwe...